Head-To-Head Contrast: Aditxt (NASDAQ:ADTX) & Incannex Healthcare (NASDAQ:IXHL)

Incannex Healthcare (NASDAQ:IXHL) and Aditxt (NASDAQ:ADTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Earnings and Valuation

This table compares Incannex Healthcare and Aditxt”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90,000.00	316.54	-$19.30 million	($1.69)	-1.34
Aditxt	$14,336.00	0.03	-$41.71 million	($100,788.35)	-0.00

Incannex Healthcare has higher revenue and earnings than Aditxt. Incannex Healthcare is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Incannex Healthcare has a beta of 7, meaning that its share price is 600% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.

Profitability

This table compares Incannex Healthcare and Aditxt’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-25.62%	-24.46%
Aditxt	-360,152.50%	-374.60%	-105.93%

Institutional & Insider Ownership

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Incannex Healthcare and Aditxt, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	2	0	1	0	1.67
Aditxt	1	0	0	0	1.00

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 692.95%. Given Incannex Healthcare’s stronger consensus rating and higher probable upside, equities analysts plainly believe Incannex Healthcare is more favorable than Aditxt.

Summary

Incannex Healthcare beats Aditxt on 12 of the 14 factors compared between the two stocks.

About Incannex Healthcare

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.